TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03715829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: Maintenance dose A. Oral tablet taken QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: Maintenance dose A. Oral tablet taken QD
Study: NCT02750943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannous Fluoride
Description: Dentifrice containing 0.454% w/w stannous fluoride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Monofluorophosphate
Description: Dentifrice containing 1000ppm fluoride as sodium monofluorophosphate
Study: NCT00814788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: 50 mg oral tablet daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg oral capsule daily
Study: NCT01467583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Description: 2.5 mg every 48 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Description: 2.5 mg every 48 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Description: 2.5 mg every 48 hours
Study: NCT03177291

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone
Description: Pirfenidone: 267 mg Capsules by mouth (PO) 3 times per day (TID). Dose Escalation: Level 1:One capsule (total daily dose 801 mg); Level 2: Two capsules (total daily dose 1602 mg); Level 3: Three capsules (total daily dose 2403 mg).~Dose Expansion: Treatment at dose determined by the Phase 1 Dose Escalation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone
Description: Pirfenidone: 267 mg Capsules by mouth (PO) 3 times per day (TID). Dose Escalation: Level 1:One capsule (total daily dose 801 mg); Level 2: Two capsules (total daily dose 1602 mg); Level 3: Three capsules (total daily dose 2403 mg).~Dose Expansion: Treatment at dose determined by the Phase 1 Dose Escalation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Area under the curve (AUC) 6 on Day 1 of a 21-day cycle for 4 - 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Area under the curve (AUC) 6 on Day 1 of a 21-day cycle for 4 - 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 200 mg/m\^2 on Day 1 of a 21-day cycle for 4 - 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/m\^2 on Day 1 of a 21-day cycle for 4 - 6 cycles.
Study: NCT03306927

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole yellow pea chili
Description: Chili containing whole yellow peas

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Split yellow pea chili
Description: Chili containing split yellow peas

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rice chili
Description: Chili containing long grain white rice

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rice chili
Description: Chili containing long grain white rice
Study: NCT03036319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: Participants will receive active tDCS at up to 4mA per electrode for up to 40 minutes for up to 260 sessions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: Participants will receive active tDCS at up to 4mA per electrode for up to 40 minutes for up to 260 sessions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: Participants will receive active tDCS at up to 4mA per electrode for up to 40 minutes for up to 260 sessions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: Participants will receive active tDCS at up to 4mA per electrode for up to 40 minutes for up to 260 sessions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: Participants will receive sham tDCS for up to 260 sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: Participants will receive sham tDCS for up to 260 sessions

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS
Description: Participants will receive sham tDCS for up to 260 sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: Participants will receive sham tDCS for up to 260 sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitively based intervention
Description: Participants may receive a cognitively based intervention that targets the particular cognitive and/or functional abilities of interest. This includes methods of cognitive training, cognitive remediation, and cognitive rehabilitation for up to 260 sessions
Study: NCT02890199

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Study: NCT03036319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitively based intervention
Description: Participants may receive a cognitively based intervention that targets the particular cognitive and/or functional abilities of interest. This includes methods of cognitive training, cognitive remediation, and cognitive rehabilitation for up to 260 sessions
Study: NCT03715829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: Maintenance dose A. Oral tablet taken QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: Maintenance dose A. Oral tablet taken QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: Maintenance dose A. Oral tablet taken QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: Maintenance Dose B. Oral tablet taken QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: Maintenance Dose B. Oral tablet taken QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: Maintenance Dose C. Oral tablet taken QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF06700841
Description: Oral tablet taken QD
Study: NCT03715829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: narrow-band UVB phototherapy
Description: Phototherapy will be combined with PF-06651600
Study: NCT03036319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitively based intervention
Description: Participants may receive a cognitively based intervention that targets the particular cognitive and/or functional abilities of interest. This includes methods of cognitive training, cognitive remediation, and cognitive rehabilitation for up to 260 sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tACS
Description: Participants will receive active transcranial alternating current stimulation at up to 4mA per electrode for up to 40 minutes for up to 260 sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tACS
Description: Participants will receive active transcranial alternating current stimulation at up to 4mA per electrode for up to 40 minutes for up to 260 sessions
Study: NCT00764426

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: red wine, beer, ethanol
Description: Alcoholic beverages equivalent to 30g of alcohol per day for men and 20g/d for women for 3 weeks
Study: NCT03036319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tACS
Description: Participants will receive active transcranial alternating current stimulation at up to 4mA per electrode for up to 40 minutes for up to 260 sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tACS
Description: Participants will receive active transcranial alternating current stimulation at up to 4mA per electrode for up to 40 minutes for up to 260 sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tACS
Description: Participants will receive sham transcranial alternating current stimulation for up to 260 sessions
Study: NCT00860340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 100 mg tablet of Spironolactone (Aldactone) by mouth with half a glass of water.
Study: NCT03036319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tACS
Description: Participants will receive sham transcranial alternating current stimulation for up to 260 sessions

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tACS
Description: Participants will receive sham transcranial alternating current stimulation for up to 260 sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tACS
Description: Participants will receive sham transcranial alternating current stimulation for up to 260 sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tRNS
Description: Participants will receive active transcranial random noise stimulation at up to 4mA per electrode for up to 40 minutes for up to 260 sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tRNS
Description: Participants will receive active transcranial random noise stimulation at up to 4mA per electrode for up to 40 minutes for up to 260 sessions
Study: NCT00764426

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: de-alcoholised red wine, de-alcoholised beer, water
Description: de-alcoholised red wine, de-alcoholised beer, water
Study: NCT03036319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tRNS
Description: Participants will receive active transcranial random noise stimulation at up to 4mA per electrode for up to 40 minutes for up to 260 sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tRNS
Description: Participants will receive active transcranial random noise stimulation at up to 4mA per electrode for up to 40 minutes for up to 260 sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tRNS
Description: Participants will receive sham transcranial random noise stimulation for up to 260 sessions
Study: NCT04634136

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lab tests
Description: CBC and differential counts, blood electrolytes, magnesium, calcium, phosphorus, urea \& creatinine, liver enzymes (AST, ALT, gGT)

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Lab tests
Description: CBC and differential counts, blood electrolytes, magnesium, calcium, phosphorus, urea \& creatinine, liver enzymes (AST, ALT, gGT)
Study: NCT03036319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tRNS
Description: Participants will receive sham transcranial random noise stimulation for up to 260 sessions

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tRNS
Description: Participants will receive sham transcranial random noise stimulation for up to 260 sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tRNS
Description: Participants will receive sham transcranial random noise stimulation for up to 260 sessions
Study: NCT02211859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 2536
Study: NCT04634136

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ECG
Description: Electrocardiogram

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: ECG
Description: Electrocardiogram
Study: NCT01187199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
Study: NCT03015740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01187199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Starting dose 30 mg/m2 given by vein on day 1 of a 21 day cycle.
Study: NCT04634136

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Edmonton symptom assessment system
Description: Edmonton symptom assessment system and general impression scale (1 - very much improved; 7 - very much worse).
Study: NCT03015740

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Given PO
Study: NCT01187199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Starting dose 200 mg by mouth daily for a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Starting dose AUC 2 by vein on day 1 of a 21 day cycle.
Study: NCT03805646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Phone-based Triage Tool
Description: The proposed intervention is a mobile phone-administered survey. Participants that have been admitted to participating hospitals for treatment of injury will be contacted by mobile phone approximately two weeks after discharge. A seven-question survey will be administered over the phone to each participant. Cross-validation with a separately administered in-person physical exam will be performed to assess the survey tool's prediction of who needs further care for treatment of their injury.
Study: NCT02016872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FMISO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET/CT
Study: NCT00798265

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil
Description: .5 mL dose injected intramuscular (IM) at 0, 2 and 6 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil
Description: .5 mL dose injected intramuscular (IM) at 0, 2 and 6 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil
Description: .5 mL dose injected intramuscular (IM) at 0, 2 and 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey
Description: Administration of online risk behavior and knowledge survey done at week 0.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey
Description: Administration of online risk behavior and knowledge survey done at week 0.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Survey
Description: Administration of online risk behavior and knowledge survey done at week 0.
Study: NCT04207255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opaganib
Description: 500mg of Opaganib orally twice a day continuously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opaganib
Description: 500mg of Opaganib orally twice a day continuously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: IV as directed by SOC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: IV as directed by SOC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: IV as directed by SOC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: IV as directed by SOC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opaganib
Description: 250mg of Opaganib orally twice a day continuously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opaganib
Description: 250mg of Opaganib orally twice a day continuously.
Study: NCT03116022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estriol
Description: Women using drug 1 mg / 1g in the proximal third of the vagina every other night for 12 weeks
Study: NCT00616096

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immunoadsorption
Description: First cycle: week 1, day 1-5~Second cycle: week 5, day 1-5
Study: NCT02476331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working memory training
Description: The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). The experimental group will complete the working memory training, which involves three games: N-back, Multi-Memory, and Moving Memory. These games are designed to engage processes involving updating and manipulation of information. All of the training games provided by BrainGymmer are adaptive, meaning that the level of difficulty increases as users develop expertise on a given task. Participants randomized to the cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
Study: NCT00812318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 10 mg oral solution
Description: GSK1265744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 5 mg tablet
Description: GSK1265744 5mg tablet, fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 5 mg tablet
Description: GSK1265744 5mg tablet, fed
Study: NCT02538211

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine
Description: All subjects will be given an oral dose of the rotavirus vaccine, RotarixTM, and intramuscular injections of the Tetanus vaccine and Pneumococcal vaccine, Pneumo 23.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine
Description: All subjects will be given an oral dose of the rotavirus vaccine, RotarixTM, and intramuscular injections of the Tetanus vaccine and Pneumococcal vaccine, Pneumo 23.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine
Description: All subjects will be given an oral dose of the rotavirus vaccine, RotarixTM, and intramuscular injections of the Tetanus vaccine and Pneumococcal vaccine, Pneumo 23.
Study: NCT01415596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salbutamol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03088007

Intervention type: OTHER
Intervention: Cognitive, adaptive, behavioral and academic assessment
Description: Cognitive, adaptive, behavioral and academic assessment will be performed if not available in the records, using WISC-IV, VABS, GECEN and an academic skills rating form.

Intervention type: OTHER
Intervention: Cognitive, adaptive, behavioral and academic assessment
Description: Cognitive, adaptive, behavioral and academic assessment will be performed if not available in the records, using WISC-IV, VABS, GECEN and an academic skills rating form.
Study: NCT01450800

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin
Description: Nitrofurantoin 100mg po daily to be taken every day the patient uses a catheter for up to one week post-operatively
Study: NCT03408314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PediQUEST Response
Description: PediQUEST Response consists of regular feedback of electronic patient reported outcomes (child symptoms and quality of life) to providers and families coupled with involvement of the palliative care team, who will meet with families and providers within three weeks of randomization and follow-up at least monthly as deemed necessary based on PediQUEST feedback reports and other clinical indications.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Cancer Care
Description: Patients assigned to the usual cancer care arm, will receive the standard care provided by participating sites + be required to complete PediQUEST surveys (but no reports will be generated).
Study: NCT03394612

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: EHSG-KF
Description: Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: EHSG-KF
Description: Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: STSG
Description: Transplantation of autologous split-thickness skin graft to the control area

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: STSG
Description: Transplantation of autologous split-thickness skin graft to the control area
Study: NCT01999101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Px-104
Description: 28 days treatment